Melanotan-1 · Research brief
Melanotan-1 (Afamelanotide): Research Overview & Lab Guide
Short answer
Melanotan-1, known by its international nonproprietary name afamelanotide and in the literature as NDP-MSH, is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone developed from academic peptide chemistry in the 1980s. It binds the melanocortin-1 receptor. Research examines eumelanin synthesis, photoprotection, receptor pharmacology, and pharmacokinetic behavior in laboratory and early clinical settings.
Key takeaways
- Melanotan-1 (afamelanotide, NDP-MSH) is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone, modified with norleucine at position 4 and D-phenylalanine at position 7 for greater metabolic stability than the native hormone.
- Its reported mechanism centers on melanocortin-1 receptor (MC1R) binding, cAMP signaling, and upregulation of eumelanin synthesis — a pathway characterized largely in cell and rodent models.
- Published reviews focus most heavily on photoprotection in erythropoietic protoporphyria, with smaller exploratory work in other photodermatoses and pigmentary conditions; much of that evidence remains preliminary.
- Nearly all clinical literature involves a controlled-release implant formulation, not research-grade lyophilized peptide, so the two are not interchangeable for interpretation purposes.
- Research-grade Melanotan-1 is not an approved medicine for any use discussed here and is intended for research use only, handled by qualified personnel under institutional oversight.
- Sourcing diligence rests on batch-specific third-party COAs: RP-HPLC purity, mass spectrometry identity, net peptide content, and lot traceability.
Melanotan-1, known by its international nonproprietary name afamelanotide and in the literature as NDP-MSH, is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone developed from academic peptide chemistry in the 1980s. It binds the melanocortin-1 receptor. Research examines eumelanin synthesis, photoprotection, receptor pharmacology, and pharmacokinetic behavior in laboratory and early clinical settings.
What Melanotan-1 Is and Where It Came From
The parent molecule, α-MSH, is an endogenous melanocortin peptide cleaved from pro-opiomelanocortin. It signals pigment cells efficiently but is degraded quickly by circulating peptidases, which makes the native hormone impractical as a research probe for sustained receptor activation. Melanotan-1 was designed to solve that problem through two targeted substitutions: norleucine replaces methionine at position 4, and D-phenylalanine replaces the L-isomer at position 7. Both changes reduce susceptibility to enzymatic cleavage, and the D-amino acid substitution also stabilizes the bioactive conformation. Reported assays describe the analogue as substantially more potent and longer-acting at the receptor than the native hormone.
The resulting sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, with a molecular formula of C78H111N21O19 and an average molecular weight near 1646.9 Da. The same molecule appears in the literature under several labels — afamelanotide, NDP-MSH, NDP-α-MSH, melanotan I, MT-1, and the older development code CUV1647. These are naming conventions, not different compounds, which is a common source of confusion when researchers compare datasets across decades.
Melanotan-1 should not be conflated with Melanotan-2, a separate cyclic lactam analogue with a shorter backbone and a broader melanocortin receptor profile. The two are frequently discussed together because both engage pigmentary pathways, but their receptor selectivity, reported effect profiles, and research histories diverge meaningfully.
Reported Mechanism of Action
The mechanism described across the review literature is receptor-mediated and reasonably well mapped at the cellular level. Melanotan-1 binds MC1R, a Gs-coupled receptor expressed on melanocytes and on several other cell types including keratinocytes and immune cells. Receptor engagement activates adenylyl cyclase, raising intracellular cAMP, which activates protein kinase A and CREB-driven transcription. Downstream, microphthalmia-associated transcription factor (MITF) upregulates tyrosinase, TRP-1, and DCT — the enzymatic machinery of melanogenesis.
The pigment shift reported in these models is qualitative as well as quantitative: the pathway favors eumelanin, the darker, more photostable polymer, over pheomelanin. Eumelanin absorbs and scatters ultraviolet radiation and shows reactive oxygen species-quenching behavior in vitro, which is the basis for interest in photoprotective research endpoints rather than any cosmetic framing.
Beyond pigment, MC1R signaling has been linked in cell and rodent work to anti-inflammatory and antioxidant effects, including modulation of NF-κB signaling and reported influence on nucleotide excision repair activity following UV exposure. These are mechanistic observations from controlled models, and the extent to which they translate to intact organisms remains an open question. Naturally occurring MC1R loss-of-function variants — the ones associated with red hair and poor tanning phenotypes — are frequently cited as a reason inter-individual response varies, and they represent a recurring variable in study design.
| Attribute | Melanotan-1 (afamelanotide) | Melanotan-2 |
|---|---|---|
| Structure | Linear 13-residue α-MSH analogue | Cyclic lactam heptapeptide analogue |
| Receptor profile | Reported as MC1R-preferring | Broader melanocortin activity, including MC3R/MC4R |
| Primary research focus | Pigmentation and photoprotection endpoints | Mixed pigmentary and non-pigmentary endpoints |
| Clinical literature depth | Multiple published reviews and controlled trials | Largely case reports and preclinical work |
What the Research Literature Examines
Photoprotection in erythropoietic protoporphyria
The largest and most consistent body of published work concerns erythropoietic protoporphyria, a rare inherited photodermatosis in which accumulated protoporphyrin drives severe phototoxic reactions. Multiple reviews across the 2010s and 2020s summarize controlled trials in which a slow-release implant formulation of afamelanotide was associated with increased tolerance to light exposure and reduced frequency of phototoxic episodes compared with placebo. This is the indication for which regulatory authorization was granted in certain jurisdictions for that specific implant product — a formulation and clinical context entirely distinct from research-grade lyophilized peptide.
Other photodermatoses and pigmentary conditions
A 2020s review describing broader dermatologic potential catalogues exploratory work in polymorphic light eruption, solar urticaria, vitiligo studied alongside narrowband UVB phototherapy, and photosensitivity associated with other conditions. Sample sizes in most of this work are small, control arms are often absent, and follow-up is short. The literature itself describes these applications as investigational; evidence remains preliminary and should be read as hypothesis-generating rather than settled.
Hailey-Hailey disease
Clinical work published in the mid-2010s evaluated the melanocortin analogue in a small number of patients with Hailey-Hailey disease, a rare acantholytic disorder, and reported lesion improvement in treated individuals. The cohort was very small and the finding has not been widely replicated, so it functions best as a signal for further mechanistic investigation into MC1R signaling in keratinocyte adhesion and inflammation.
Pharmacokinetics and pharmacodynamics
A dedicated pharmacokinetic review reports a pattern that recurs throughout the field: the peptide itself is cleared from circulation relatively quickly, while the pharmacodynamic response — measured as melanin density — rises over days and persists for weeks after plasma concentrations have fallen. This dissociation between exposure and effect is central to interpreting any study, because plasma half-life is a poor proxy for duration of biological response. It also explains why controlled-release formulations dominate the clinical literature.
An interpretive caution
Almost every clinical dataset on afamelanotide derives from a specific controlled-release implant administered under medical supervision. Research-grade lyophilized peptide is a different physical product with different release characteristics. Extrapolating outcome data from one to the other is not straightforward, and careful investigators state that limitation explicitly in their methods.
Laboratory Handling: Reconstitution and Storage
Melanotan-1 is typically distributed as a lyophilized powder in sealed vials. Standard peptide handling practice applies. Vials are generally allowed to equilibrate to ambient temperature before opening so that condensation does not introduce moisture into hygroscopic powder. Reconstitution is performed with an appropriate sterile diluent introduced slowly along the vial wall rather than directly onto the cake, followed by gentle swirling; vigorous agitation can shear peptide chains and promote aggregation or foaming.
Lyophilized material is generally held cold, sealed, and protected from light, with long-term holding at lower temperatures than short-term. Once in solution, peptides are markedly less stable: refrigerated storage, minimal headspace, protection from light, and aliquoting to avoid repeated freeze-thaw cycles are the usual controls. The tryptophan residue at position 9 makes the molecule photosensitive, so amber vials or light-shielded storage is common practice. Notably, the norleucine substitution at position 4 eliminates the oxidation-prone methionine of native α-MSH, which is one reason the analogue is described as more robust than the parent hormone.
Good documentation matters as much as good technique. Recording lot number, diluent identity, reconstitution date, and storage conditions allows anomalous results to be traced back to a material variable rather than attributed to biology. Deeper procedural detail — solvent selection, stability windows, refrigeration questions — is covered across the dedicated handling and storage resources in this topic cluster.
Regulatory and Research-Use Status
Research-grade Melanotan-1 is not a medicine. It is not FDA-approved for any of the applications discussed on this page, it is not approved for human or veterinary use, and it is not a dietary ingredient, cosmetic, or household chemical. The existence of regulatory authorization for a specific implant formulation in a narrow rare-disease setting does not extend to research chemicals, nor does it validate any other application.
Material offered by Real Peptides is intended for laboratory research only, to be handled by qualified personnel in an appropriate research setting under institutional oversight. That framing is not decorative — it determines documentation expectations, disposal practice, and the legal basis on which the material may be held. Investigators are responsible for confirming that their intended work complies with institutional policy and with applicable federal, state, and local regulation. This page is educational and describes published findings; it does not constitute guidance for administration to humans or animals.
How Researchers Evaluate Vendor Quality
Peptide identity and purity cannot be assessed by appearance. A white lyophilized cake tells the observer nothing about whether the correct sequence is present, how much of the vial mass is actually peptide, or what counter-ions and residual solvents came along with it. Analytical documentation is the only meaningful check, and it must be batch-specific — a COA from a different lot is decorative, not evidential.
| Analytical test | Question it answers | What to scrutinize |
|---|---|---|
| RP-HPLC purity | What fraction of peptide material is the target sequence? | A readable chromatogram, not a bare percentage; look at impurity peaks near the main peak |
| Mass spectrometry (ESI or MALDI-TOF) | Is the molecule actually afamelanotide? | Observed mass consistent with the expected ~1646.9 Da average mass |
| Net peptide content | How much of the vial mass is peptide versus water, salts, and acetate? | Whether the figure is reported at all, and by what method |
| Batch traceability | Does this document correspond to this vial? | Lot number on the COA matching the vial label and test date |
| Third-party issuance | Who performed the analysis? | An independent laboratory rather than in-house self-attestation |
Publishing COAs per batch, in full and openly, is the baseline standard a research operation should meet. Reproducibility across experiments depends on knowing that lot-to-lot variability has been characterized rather than assumed.
Where the Open Questions Are
Several gaps stand out in the current literature. Long-term consequences of sustained MC1R activation are not well characterized, and reviews consistently note that extended surveillance data are limited. The relationship between induced pigmentation and actual reduction in UV-mediated DNA damage — as opposed to increased light tolerance — has not been fully resolved. Whether the reported anti-inflammatory and antioxidant signaling contributes independently to observed outcomes, or is incidental to pigment change, remains unsettled.
Response heterogeneity driven by MC1R polymorphism is acknowledged but not systematically stratified in most published work. Applications beyond erythropoietic protoporphyria rest largely on small, uncontrolled series. And because clinical data derive overwhelmingly from one controlled-release formulation, questions about exposure-response relationships for other physical forms are essentially unaddressed. These are precisely the gaps that well-documented preclinical work is positioned to explore.
Going Deeper in This Topic Cluster
This hub sits above detailed resources on Melanotan-1 across several themes: clearance and pharmacokinetic timelines; what the observational literature reports about response progression; comparisons with Melanotan-2 and with route-of-exposure variables studied in the literature; reconstitution and storage procedure; stability and shelf-life considerations; reported adverse-effect signals; and how to read analytical documentation when evaluating a research chemical vendor. Each covers its subject in depth; this page exists to frame the compound as a whole and point toward the right one.
Explore Melanotan-1 (Afamelanotide) research on Real Peptides
The articles below go deeper on the questions researchers ask most about Melanotan-1 (Afamelanotide).
Research timelines & mechanisms
Safety & side effects
Buying & quality
Stacks & comparisons
- Melanotan-1 Stacking Guide — Real Peptides
- Melanotan 1 vs Melanotan 2: The Real Difference Explained
- Can You Stack Melanotan-1 With Other Peptides? — Real
- Melanotan-1 vs MT-1: Same Peptide, Different Name
Reconstitution, storage & handling
- How Long Melanotan-1 Vial Lasts? (Shelf Life Guide)
- Does Melanotan-1 Need Refrigeration? Storage Guide
- Melanotan-1 Storage — Temperature, Shelf Life & Stability |
- How to Store Melanotan-1 After Reconstitution — Real
Research questions
- Signs Melanotan-1 Gone Bad — Storage & Degradation Guide
- Is Scenesse the Same as Melanotan-1? (Mechanism Explained)
Legal & regulatory
- Is Melanotan-1 Legal 2026 Status — Regulatory Clarity
- Is Melanotan-1 FDA Approved Status — Regulatory Facts
References
Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.
- Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
- Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
- A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
- Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
- Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
- Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA